Availability of an HLA-identical sibling (MRD) or suitably matched unrelated donor (MUD) has historically been a limiting factor in the application of allogeneic hematopoietic transplantation. Although almost all patients have an HLA-haploidentical family donor, prior attempts at transplantation from such donors using T-cell replete grafts and conventional immunosuppression were associated with unacceptable rates of GVHD, and when stringent ex vivo T-cell depletion was used to control GVHD, rates of graft rejection and post-transplant infections were prohibitive. The recent approach to HLA-haploidentical donor transplantation developed in Baltimore that uses T-cell replete grafts and post-transplant CY (Haplo-post-HCT-CY) to control post-transplant allo-reactivity appears to have overcome many of the obstacles historically associated with haploidentical donor transplantation. In particular, TRM rates of o10% are usual and rapid reconstitution of immunity leads to a low rate of post-transplant infections and no post-tranplant lymphoproliferative disorders (PTLD), consistent with the hypothesis that post-transplant CY selectively depletes proliferating alloreactive T cells responsible for GVHD and graft rejection while preserving resting memory T cells essential for post-transplant immunologic recovery. In parallel trials using similar non-myeloablative conditioning regimens, Haplo-post-HCT-CY produced similar overall survival to double umbilical cord blood transplantation(DUCBT) in adult patients (62% vs 54%), with low rates of TRM (7% vs 24%), severe acute GVHD (0% vs 21%) and chronic GVHD (13% vs 25%). Furthermore, recent non-randomized comparisons adjusted for risk factors show that Haplo-post-HCT-CY achieve at least equivalent outcomes to conventional MRD and MUD transplants. Although most experience has been obtained using BM, emerging data suggest that a G-CSF mobilized PBSC graft can also safely be used for Haplo-post-HCT-CY. Haplo-post-HCT-CY also avoids the graft acquisition costs of DUCBT and MUDs and the cost of cell selection associated with T-depleted grafts. Although randomized comparisons will be forthcoming, Haplo-post-HCT-CY can already be considered a valid standard-of-care in patients who lack conventional donors thus extending the availability of allogeneic transplants to almost all patients. This donor source may also challenge the routine preference for a MUD in patients lacking an MRD.
INTRODUCTION AND PRIOR APPROACHES TO HAPLOIDENTICAL DONOR TRANSPLANTATION
Many patients who may benefit from allogeneic hematopoietic cell transplantation will lack a conventional HLA-identical sibling (MRD) or matched unrelated donor (MUD). This is particularly so for patients from ethnic minorities or mixed-race backgrounds. In contrast, almost all such patients will have access to a family member with whom they share one HLA-haplotype (HaploD). Early attempts at using T-replete grafts from HaploD and conventional GVHD prophylaxis regimens were associated with severe allo-reactivity resulting in unacceptable rates of GVHD and graft rejection. [1] [2] [3] [4] Attempts to overcome these barriers using the combination of intense preparative regimens and stringent ex vivo/in vivo T-cell depletion have proved feasible. [5] [6] [7] However, even in highly experienced centers, such T-depleted HaploD transplants have been associated with poor immune reconstitution and high rates of mortality from post-transplant infections and regimen-related toxicity. 7 Recent approaches to haploidentical donor transplantation other than post-transplant CY In order to control both the risk of GVHD and graft rejection, investigators from Perugia have used very high doses ('megadose') of purified CD34 + cells (median >10 × 10 6 per kg) with very few contaminating T cells (median 1 × 10 4 /kg) using both positive and negative selection in conjunction with an intense preparative regimen. 8 Although engraftment was obtained in 94 of 101 evaluable patients and GVHD was well controlled, non-relapse mortality was high (36.5%) and largely caused by infections associated with slow immunologic recovery post transplant. Event-free survival was adequate in patients in remission at the time of transplant but was poor in patients with active malignancy. The complexity of this approach has limited its adoption to other centers. More recently, the Perugia group has developed a more complex strategy involving the administration of isolated donor-derived regulatory T cells on day -4 followed by administration of both selected CD34 + cells and a dose of
The authors claimed that this approach reduced the incidence of GVHD and improved immune reconstitution compared with that seen in prior Perugia protocols without the use of regulatory T cells. Although this modification of their approach appears to ameliorate the issue of poor immune reconstitution post transplant, the extensive cell selection used limits the potential transferability of this approach to other centers. The group at Peking University in China have used an approach that eschews ex vivo T depletion, but uses an intense preparative regimen that includes in vivo T depletion with anti-thymocyte globulin and a graft composed of both G-CSF mobilized PBSC and G-CSF-stimulated BM. GVHD prophylaxis consisted of cyclosporine A, methotrexate and mycopheolate mofetil (MMF). In 250 patients with leukemia treated using this approach they reported almost universal full-donor chimerism with acute and chronic GVHD rates of 46% and 54%, respectively. 10 Although leukemia-free survival was good in standard-risk patients, opportunistic infections were frequent, and TRM for standard-risk and high-risk groups was 19.5% and 29.5% for AML and 21% and 51% for ALL, respectively. Rizzieri et al.
11 used non-myeloablative conditioning regimen based on fludarabine and CY for HaploD transplantation. In vivo but not ex vivo T depletion using alemtuzumab (100 mg) was used to control allo-reactivity together with post-transplant MMF with or without cyclosporine following G-CSF-mobilized PBSC grafts. Although rates of acute and chronic GVHD were low and non-engraftment was seen in only 8%, non-relapse mortality at 2 years was in excess of 40% presumably from infections. The above approaches are summarized in Table 1 .
USE OF POST-TRANSPLANT CY TO SELECTIVELY CONTROL ALLO-REACTIVITY FOLLOWING T-REPLETE NON-MYELOABLATIVE HAPLOIDENTICAL DONOR TRANSPLANTATION
Recent interest has focused on an approach developed in Baltimore that utilizes high-dose post-transplant CY (ptCY) to selectively deplete alloreactive T cells following T-replete HaploD transplantation (Haplo-post-HCT-CY). The ability of pt CY to tolerize recipients to a graft was first demonstrated in a skin-allografting model in the 1960s. 12 This technique relies on the increased sensitivity of proliferating (allo-antigen-stimulated) vs resting/memory T cells to the cytotoxic effects of ptCY as suggested by the fact that administration of cyclosporine A between allografting and administration of CY led to an abrogation of tolerance. 13 Application of ptCY at the correct time following infusion of HaploD cells can thus be used to eliminate highly activated and proliferative T cells responsible for severe GVHD and graft rejection while sparing quiescent memory T cells responsible for immunity to infections. Furthermore, pluripotent hematopoietic stem cells in the graft appear to contain high levels of aldehyde dehydrogenase which makes them resistant to the toxic effects of ptCY ensuring that the hematopoietic cells in the graft are not ablated.
14 Using a murine model, Luznik et al. 15 demonstrated that ptCY administered on day +3 can allow stable engraftment across MHC barriers when used in conjunction with pre-transplant fludarabine and low-dose TBI. Both the incidence of GVHD and the dose of donor cells required for engraftment were substantially reduced by the use of ptCY. More recent investigations have demonstrated that alloreactive T cells proliferating in response to antigen (that is, those responsible for GVHD and graft rejection) are much more susceptible to the effects of ptCY than memory T cells (such as those responsible for immunity to pathogens post transplant) which proliferate more slowly in response to lymphopenia. 16 Furthermore, CD4(+)CD45RA(− )Foxp3 (+hi) effector regulatory T cells express high levels of aldehyde dehydrogenase and appear to readily survive the use of high-dose CY and may contribute to the prevention of GVHD following Haplo-post-HCT-CY. 17 Based upon some of these observations, the group at Johns Hopkins University translated this approach into a clinical protocol of HaploD transplantation using a non-myeloablative conditioning regimen (pre-transplant fludarabine (150 mg/m 2 ), CY (29 mg/kg) and 2 Gy TBI, a T-replete BM graft followed by ptCY (50 mg/kg on d+3), MMF (day 4 to 35) and tacrolimus (day 4 to >50). 18 They demonstrated that donor engraftment without severe GVHD occurred in eight of ten patients treated on this regimen. The dose of ptCY was subsequently increased to 100 mg/kg and results of 68 patients transplanted using this approach were published in 2008. 19 They further demonstrated that graft failure occurred in 13% of cases and almost every case was associated with autologous recovery. Although engrafting patients generally developed full-donor T-cell chimerism by d28, cumulative incidence of grade III-IV acute GVHD was only 6% and chronic GVHD developed in only 5% treated with 100 mg/kg ptCY. Consistent with the low rates of GVHD and infections, nonrelapse mortality at 1 year was 15%. Cumulative incidence of relapse at one year was 51% likely related to the advanced malignancies treated and the non-myeloablative conditioning regimen used. Similar outcomes were seen in 50 patients treated on a multi-center phase II study of this regimen conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN). 20 Unlike with prior approaches to HaploD transplantation, greater degrees of HLA-disparity between HaploD and recipient for the non-shared haplotype were not associated with a higher rate of acute GVHD or NRM but a trend to a lower relapse risk an improved EFS. 21 Although donor BM has been the graft source in most cases, some investigators have substituted G-CSF-mobilized PBSC as the graft source in selected patients without observing an increase in rates of GVHD or NRM (O'Donnell, P-personal communication and Bashey, unpublished data) although no formal comparisons have been reported.
USE OF POST-TRANSPLANT CY TO FACILITATE HLA-HAPLOIDENTICAL DONOR TRANSPLANTS USING A MYELOABLATIVE CONDITIONING REGIMEN
Studies of non-myeloablative Haplo-post-HCT-CY show remarkable tolerability of this approach with low rates of GVHD, infection and TRM. Relapse of malignancy remains the predominant cause of treatment failure. Non-myeloablative Haplo-post-HCT-CY are associated with an approximately 10% rate of engraftment failure resulting in autologous recovery even in the absence of detectable pre-transplant anti-donor antibodies in the recipient. The use of more intense/myeloablative preparative regimens and PBSC grafts may potentially reduce the rate of relapse and graft rejection following Haplo-post-HCT-CY transplants. However, only a limited number of such studies has been reported. Grosso et al. 22 reported a two-step strategy where defined dose of haploidentical T cells (2 ×10 8 /kg) were infused after myeloablative doses of TBI. Patients then received 60 mg/kg of CY on two consecutive days to induce bidirectional tolerance followed later by highly purified CD34 + cells from the donor. The study reported a cumulative incidence of severe (grade III-IV) acute GVHD of 7.4% and NRM rate of 22.5% for the 27 patients treated. With a median follow-up of 40 months, overall survival was 48%. The requirement for stringent ex vivo T depletion of the hematopoietic cell product differentiates this approach from that pioneered in Baltimore and may limit its widespread applicability. Furthermore, given the resistance of hematopoietic stem cells to CY, such delayed infusion of selected CD34 + cells may be unnecessary. In contrast, our group has developed protocols using myeloablative conditioning and PBSC grafts used without any ex vivo T depletion or in vivo serotherapy directed against T cells ( Figure 1 ). Twenty patients were initially treated on a conditioning regimen T-cell replete haploidentical donor transplantation A Bashey and SR Solomon Figure 1 ). The majority of patients treated had high-risk (relapsed/refractory) disease. All patients engrafted and demonstrated 100% donor chimerism in both peripheral blood CD3+ and CD33+ cells from day +30. Cumulative incidence of NRM at 12 m was 10% and that of grade III-IV acute GVHD and severe chronic GVHD were 10% and 5%, respectively. With a median follow-up of 20 months, estimated probabilities of overall and disease-free survival (DFS) were 69% and 50%, respectively. There were no cases of invasive mold infections or EBV-related PTLD. Only one patient had CMV disease and only one patient died of a viral infection (parainfluenza 3) suggesting that anti-infection immunity was well preserved with this approach. Non-fatal BK virusassociated cystitis was seen in 75% of patients at a median of 38 days post-transplant. We hypothesized that this was predisposed to by the combined effect of high-dose busulfan and fludarabine with pre and post-transplant CY. Indeed, in a subsequent clinical trial which eschews high-dose busulfan for a myeloablative regimen of pre-transplant fludarabine and 1200 cGy TBI with standard ptCY, MMF and tacrolimus (NSH 922; Figure 1 ) has had a much lower incidence of BK virus-associated cystitis. 24 Symons et al. 25 reported on 27 Haplo-post-HCT-CY patients treated using a myeloablative regimen consisting of busulfan (targeted to 800-1400 micromol min/l) on d − 6 to − 3 and CY 50 mg/kg/d on d − 2 and − 1, followed by a BM graft. 25 Three additional patients received a TBI-based conditioning regimen. All but one patient engrafted. Estimated probabilities of NRM and severe (grade III-IV) acute GVHD at 100 days were 12% and 7%, respectively. There were no deaths from infection, but cumulative incidence of relapse was 66% in the poor-risk population they treated.
Raiola et al. 26 reported on 50 patients with hematologic malignancies who were treated with Haplo-post-HCT-CY using myeloablative conditioning and a BM graft. The regimens used were thiotepa, busulfan and fludarabine (n = 35) or TBI and fludarabine (n = 15). Differences from other reported Haplo-post-HCT-CY protocols included the use of cyclosporine A starting on day 0 and MMF starting day +1 rather than day +5 as suggested by the Baltimore group. The second dose of CY was also delayed from day +4 to +5. The significance of these changes is unclear--experimental models would suggest that the administration of immunosuppressive drugs between transplant and post-transplant CY may impair the effective elimination of alloreactive cells 13 perhaps leading to a higher risk of graft rejection and GVHD. Forty-five patients (90%) engrafted with full-donor chimerism on day +30. With a median follow-up for surviving patients of 333 days (range 149-623 days), the cumulative incidence of TRM was 18%, and the rate of relapse was 26%. The estimated 22-month DFS rate was 68% for patients in remission and 37% for patients with active disease. Reported incidences of acute and chronic GVHD were low. As in the studies from Atlanta, hemorrhagic cystitis was more common in patients receiving busulfan rather than TBI-based conditioning.
These studies demonstrate that the post-transplant combination of 100 mg/kg CY, MMF and tacrolimus developed in conjunction with non-myeloablative HaploD transplantation can also prevent fatal allo-reactivity following myeloablative conditioning and either BM or G-CSF-mobilized PBSC grafts without severely impairing immune reconstitution. The rate of graft rejection appears lower in studies utilizing PBSC rather than BM. Hemorrhagic cystitis may be a cause of post-transplant morbidity especially when high-dose busulfan-based regimens are used. Studies of Haplo-post-HCT-CY are shown in Table 2 . Elements of donor selection for Haplo-post-HCT-CY and practical issues relating to such transplants are shown in Table 3 and  Table 4 , respectively. T-cell replete haploidentical donor transplantation 
T-cell replete haploidentical donor transplantation A Bashey and SR Solomon

FUTURE STATUS OF HAPLO-POST-HCT-CY VS OTHER FORMS OF ALTERNATIVE DONOR AND MUD TRANSPLANTATION Direct comparison with T-depleted haploidentical transplants
Data from studies of Haplo-post-HCT-CY have demonstrated much lower rates of TRM and infections than those seen following prior approaches to HaploD transplant that have used stringent ex vivo T depletion of the graft. However, direct comparison of the efficiacy of these two approaches have not commonly been reported. Ciurea et al. 27 compared 32 consecutive Haplo-post-HCT-CY transplants to 33 consecutive TCD HaploD transplants performed at their center. Both groups received identical preparative regimens, but in the Haplo-post-HCT-CY group GVHD prophylaxis consisted of ptCY, MMF and tacrolimus whereas patients in the TCD group received anti-thymocyte globulin (ATG) followed by the infusion of CD34-selected grafts. The Haplo-post-HCT-CY group had superior rates of OS, PFS, NRM, chronic GVHD, improved immune reconstitution and a lower rate of infections confirming the impression of superior outcomes with Haplo-post-HCT-CY.
Haplo-post-HCT-CY appears safe and effective using both reduced-intensity and myeloablative conditioning. Furthermore, it is technologically simple and does not require the use of specialized and/or expensive cell selection procedures making this approach widely applicable and easily transferred to programs with no prior experience. These findings combined with and the almost universal availability of a HaploD raises the question of whether Haplo-post-HCT-CY will eventually replace other forms of alternative donor transplantation and may even be a valid option for patients in whom a conventional donor such as a 10 of 10 or eight of eight HLA locus-matched MUD is available.
Direct comparison with umbilical cord blood transplantation
Unrelated donor umbilical cord bloodunit transplantation (UCBT) is the most widely used alternative donor option in patients who lack a conventional MRD and MUD. Advantages of UCBT include widespread availability and ethnic diversity of cord blood units (CBU) as well as the capacity to tolerate greater degrees of HLA mismatch than is possible using volunteer MUD. However, delayed hematopoietic recovery and slow immune reconstitution and acquisition cost remain important challenges. Use of two CBU (double umbilical cord blood transplantation, DUCBT) is usually necessary to provide an adequate cell dose for adult patients further raising the cost of the procedure. The studies reported above suggest that Haplo-post-HCT-CY can be a valid alternative to DUCBT in adult patients lacking a conventional donor. No randomized comparisons of Haplo-post-HCT-CY with DUCBT have yet been reported. The BMT-CTN assessed these approaches in two parallel phase II studies for patient with high-risk leukemia or lymphoma who lacked a conventional donor. 20 A similar nonmyeloablative preparative regimen incorporating CY, fludarabine and 200 cGy TBI was used in each study. Eligibility and assessments were identical. Neutrophil recovery to ANC 500/μL occurred at a median of 16 day and 15 day for Haplo-post-HCT-CY and DUCBT, respectively. However, the corresponding median times to platelet recovery to 50 000/mL were 26 days and 43 days. Acute GVHD grade III-IV occurred in 0% vs 21%, respectively. Oneyear estimated probabilities were as follows for Haplo-post-HCT-CY vs DUCBT: NRM-7% vs 24%; relapse 45% vs 31%; chronic GVHD-13% vs 25%; PFS-48% vs 46% and survival-62% vs 54%. These data suggest similar survival outcomes for the two approaches although the lower incidence of severe acute and chronic GVHD following Haplo-post-HCT-CY may result in an improved quality of life. DUCBT is associated with delayed recovery of T-cell subsets and impaired thymopoiesis when compared with conventional donor transplantation 28, 29 and is associated with higher rates of infection in the early posttransplant period. 28, 29 Consistent with this is the finding that while EBV-associated PTLD is uncommon following conventional donor transplantation, 30 it is relatively common following DUCBT. 31, 32 In contrast, immune recovery following Haplo-post-HCT-CY is more robust resulting in low rates of infection-related mortality and PTLD which appear to be significantly lower than that seen following DUCBT. 33, 34 A formal randomized phase III comparison of reduced-intensity conditioning (RIC) Haplo-post-HCT-CY vs RIC DUCBT using the regimens used in the parallel phase II studies. 20 is now underway. However, until that study is completed, the evidence hitherto available suggests that Haplo-post-HCT-CY may be associated with superior rates of platelet recovery, NRM, severe acute and chronic GVHD and infection-related mortality than DUCBT. 20, 23, [27] [28] [29] [33] [34] [35] In the parallel phase II studies conducted by the BMT-CTN, DUCBT was associated with a somewhat lower incidence of relapse than Haplo-post-HCT-CY (31% vs 45%). However, relapse risk is very subject to selection bias (for example, the Haplo-post-HCT-CY study included more patients with advanced leukemias) and can only be adequately assessed in the context of a large randomized phase III comparison. Another significant advantage to Haplo-post-HCT-CY over DUCBT is likely to be related to the much lower acquisition cost of a HaploD graft (no direct cost to acquire other than cost of harvest or PBSC collection) in comparison to two UCB units (direct acquisition cost >$80 000 in many cases). Novel strategies for CBU expansion that are in development may potentially allow the use of a single CBU for most adult patients thus reducing acquisition costs. However, Table 3 . Donor selection for haploidentical transplantation using post-transplant CY
Screen recipient for antibodies targeting mismatched donor HLAs (donor-specific antibodies, DSA)
• Screen all potential donors using solid-phase immunoassay (SPI) and cross-match of receipient serum against donor T and B lymphocytes • Select donors with negative spi screen or low-level positivity (o 1000 mean fluorescence intensity, MFI); if no negative donors available, and a negative anti-donor cross-match • Donors with a negative cross-match and positive SPI screen may potentially be desensitized 44 but such donors should only be used if the anti-donor cross-match is negative following desensitization and is safer when using nonmyeloablative conditioning 2. Choose a HLA-haploidentical donor with the greatest number of mismatches with the recipient on the non-shared haplotype
• 4 of 8 HLA-A, B, C and DRB1 matched donors appear to have a lower relapse rate and no increase in GVHD or graft rejection when compared to 5 of 8 and 6 of 8 matched donors. 21 Thus, choose a haploidentical donor with the greatest number of HLA mismatches with the recipient on the non-shared haplotype T-cell replete haploidentical donor transplantation A Bashey and SR Solomon these approaches at CBU expansion remain experimental and may result in significantly increased processing costs once commercialized. Thus, unless DUCBT is shown to have a significant advantage in controlling malignancy or some other unexpected benefit over Haplo-post-HCT-CY in the ongoing randomized comparison, the advantages of simplicity, safety and costs will likely hand the future advantage to Haplo-post-HCT-CY for patients who lack a conventional donor.
Comparison to conventional MRD and MUD transplants The safety and efficacy and potential cost benefits of Haplo-post-HCT-CY over DUCBT discussed in the above studies has generated interest in comparison of this form of therapy against conventional MUD and MRD transplantation. There have been no prospective randomized comparisons. We retrospectively compared outcomes of 53 consecutive Haplo-post-HCT-CY to 117 MRD and 101 MUD transplants contemporaneously performed at our center. 36 The three groups were comparable for patient and disease characteristics except that Haplo-post-HCT-CY patients were more likely to receive BM grafts and a RIC regimen. All patients received treatment primarily in the outpatient setting with inpatient admission for complications. The same institutional supportive care algorithms were used for patients from all three donor groups. Survival outcomes were adjusted for these differences using a Cox analysis. At two years, respective rates for HaploD vs MUD vs MRD transplants were 7%, 16% and 13% for NRM, 33%, 34% and 34% for relapse, 60%, 52% and 53% for DFS and 64%, 67% and 76% for survival. The cumulative incidences of extensive and severe chronic GVHD were lower in Haplo-post-HCT-CY patients than those receiving MUD or MRD transplants. Another retrospective comparison was performed in patients who received an allogeneic transplant specifically for relapsed/ refractory Hodgkin lymphoma in Seattle or Baltimore using Table 4 . Post-transplant issues following T-replete haploidentical transplants using post-transplant CY 1. High fevers and rigors are common between day 0 and day +5, especially when haplo-post-HCT-CY transplants are performed using myeloablative conditioning
• Presumably due to cytokine release during period of intense allo-reactivity • Reassure patients, use non-immunosuppressive supportive care measures • Treat empirically for neutropenic fever 2. Avoid all immunosuppressive medications between stem cell infusion and completion of post-transplant CY (day − 1 to +5) -may compromise the efficacy of ptCY
13
• No dexamethasone for nausea or vomiting • No hydrocortisone for fevers (common due to allo-reactivity during this period)
• Do not start GVHD prophylaxis (tacrolimus, MMF) until day +5
• Educate physicians, pharmacists, mid-level practitioners to prevent erroneous administration of immunosuppression
Monitoring for post-transplant infections
• Risk of infections is similar to conventional-matched sibling or MUD transplants • Post-transplant lymphoproliferative disorder is extremely rare-no routine monitoring for EBV reactivation necessary • BK virus-induced cystitis may be seen especially following ablative conditioning regimens using high-dose busulfan test for BK viruria in patients with symptomatic hemorrhagic and non-hemorrhagic cystitis. Anticholinergic therapy, bladder irrigation, intravenous or intravesicular cidofovir may be of benefit Abbreviation: MMF = mycophenolate mofetil. 
